Author Archives: Claire Lorenzi

Sept. 2021 | Caresyntax Gets BlackRock Investment in Upsized Funding Round

Caresyntax Gets BlackRock Investment in Upsized Funding Round Caresyntax, a digital platform aimed at reducing deaths from surgery-related complications, has added $30 million to an earlier funding round from investors including accounts and funds managed by BlackRock Inc., as well as specialty insurer ProAssurance Corp.

Sept. 2021 | Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced with its partner, Sumitomo Dainippon Pharma, that the product launch of TWYMEEG®1 (Imeglimin hydrochloride), 500mg tablets…

Sept. 2021 | Stryker partners with Genesis Healthcare Automation to improve surgical safety, efficiency and outcomes

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

June 2021 | Mainstay Medical Announces Limited Commercial Launch of ReActiv8® in the U.S.

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

June 2021 | Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan

Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), and Sumitomo Dainippon Pharma Co., Ltd., today announced that a new…

June 2021 | Oncimmune provides a trading update for the 12 months ended 31 May 2021 (“FY21”)

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

June 2021 | Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

May 2021 | Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Apr. 2021 | Caresyntax Raises $100 Million to Make Surgery Smarter and Safer

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Apr. 2021 | Oncimmune announces the signature of Agreements with Roche and Cedars-Sinai to profile patients using Oncimmune’s novel Infectious Disease panel

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…